|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y_(12 ) signaling pathway显示文摘Ticagrelor is the first reversibly binding oralP2Y_(12) receptor antagonist to inhibit platelet activation and has been approved by the Food and Drug Administration for the treatment of coronary artery disease. At present, the other pharmacological functions of ticagrelor remain poorly understood. The NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome plays a critical role in the innate immune system, but its excessive activation also contributes to the pathogenesis of complex diseases. In this study, we systematically examined the effects of ticagrelor on the NLRP3 inflammasome and found that ticagrelor inhibits NLRP3 inflammasome activation in macrophages independent of its classic inhibitory effect on theP2Y_(12) signaling pathway. Further mechanistic studies demonstrate that ticagrelor attenuates the oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC) by blocking chloride efflux, an effect achieved through the degradation of chloride intracellular channel proteins (CLICs) and blockade of the translocation of CLICs to the plasma membrane. Moreover, experiments on lipopolysaccharide-induced sepsis and alum-induced peritonitis in mice confirmed that ticagrelor mitigates the severity of systemic inflammation independent ofP2Y_(12) receptor antagonism. Importantly, oral administration of ticagrelor rapidly and strongly inhibited NLRP3 inflammasome activation in peripheral blood mononuclear cells from patients with acute coronary syndrome. Overall, our study reveals a novel pharmacological function of ticagrelor in addition to its classic antiplatelet properties, which suggests that ticagrelor may serve as a potential therapeutic agent for use in NLRP3-associated diseases. | Bo Huang Yufeng Qian Shujun Xie Xianhua Ye Hanwen Chen Zhifeng Chen Lihuan Zhang Jinming Xu Hu Hu Shenglin Ma Paul Héroux Di Wang Han-Ming Shen Yihua Wu Dajing Xia | 2021 | Cellular & Molecular Immunology2021，18，5： | 3 |
| 2 | A novel sterol from Chinese truffles Tuber indicum 显示文摘 | Jinming G Lin H Jikai L | 2001 | Steroids2001，66，10： | 1 |
| 3 | Emergence of the GII4/2006b variant andrecombinant noroviruses in China 显示文摘 | JinM Xie H Duan Z | 2008 | J Med Virol2008，80，11： | 1 |
| 4 | Toward functionalized surface through surface esterification of silica显示文摘 | Gabriel C Ossenkamp Tim Kemmitt Jinm H Johnston | 2002 | Langmuir2002，18，： | 1 |
| 5 | A novel sterol from Chinese truffles Tuber indicum显示文摘 | Jinming G Lin H Jikai L | 2001 | Steroids2001，66，10： | 1 |
| 6 | A case study of an inter-enterprise workflow-supported supply chain man-agement system显示文摘 | JIANXUN L SHENSHENG Z JINMING H | 2005 | Information&Management2005，42，3： | 1 |
| 7 | Flow injection chemiluminescent determination of trace amounts of hydrogen peroxide in snow-water using KIO4 - K2 CO3 显示文摘 | Lin Jinming Arakawa H Yamada M | 1998 | Analytica Chimica Acta1998，371，： | 1 |
| 8 | A new facile route for the preparation of single-source precursors for bulk, thin-film, and nanocrystallite semiconductors 显示文摘 | BangerK K JinM H C Harris J D | 2003 | Inorg Chem2003，42，24： | 1 |
| 9 | Rapid de- tection of atrazine and its metabolite in raw urine by extractive electrospray ionization mass spec- trometry 显示文摘 | ZHOUZQ JINM DINGJ H etal | 2007 | Metabolomics2007，3，2： | 1 |
| 10 | Modeling and control of a pow- er-split hybrid vehicle 显示文摘 | LIU Jinming PENG H | 2008 | IEEE Transactions on Con- trol Systems Technology2008，16，6： | 1 |
| 11 | Mutations in hepatitisC virus E2 located outside the CD81 binding sites lead to es-cape from broadly neutralizing antibodies but compromise virusinfectivity显示文摘 | Keck Z Y Li S H Xia Jinming | 2009 | J Virol2009，83，12： | 1 |
| 12 | Toward functional proteomics of alveolar macrophages 显示文摘 | Wu H M JinM MarshC B | 2005 | Am J Physiol Lung Cell Mol Physiol2005，288，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员